Register

COMMERCIAL SUPPORT: 

Baptist Health gratefully acknowledges the educational grants provided by Daiichi Sankyo, Inc., and AstraZeneca.

LEARNING OBJECTIVES:

• Describe institutional strategies and workflows that support prevention and proactive management of toxicities associated with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, trastuzumab deruxtecan (T-DXd), and ado-trastuzumab emtansine (TDM-1)—including antiemetic protocols, diarrhea management algorithms, growth-factor use, oral care for stomatitis, dose-modification.
• Summarize pharmacy-led safety initiatives, including creation and revision of powerplans, infusion-time optimization, prophylactic medication adjustments, and real-time integration of emerging toxicity data.
• Discuss the role of interdisciplinary collaboration—pharmacy, oncology providers, nurse educators—in educating, patients, preventing complications, and coordinating care for ADC-related adverse events.

FACULTY AND DISCLOSURES:

Diana Van Ostran, Pharm.D., BCOP
Breast Cancer Clinical Pharmacy Specialist
Miami Cancer Institute
Baptist Health South Florida

Diana Van Ostran, Pharm.D., BCOP, faculty for this educational activity, has no relevant financial relationships with ineligible companies* to disclose, and has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships with ineligible companies* to disclose.

*Ineligible companies – Companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Disclosure Policy and Disclaimer

ACCREDITATION STATEMENTS AND CREDITS

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.

Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.   

This activity has been approved for 1 credit hour, CE Broker Course #20-1346668, by the Florida Boards of Medicine, Osteopathic Medicine and Physician Assistants.  

This activity has also been approved for 1 credit for Nurse Practitioners, Nurses, Pharmacists and Pharmacy Techs, and Laboratory Personnel. Baptist Health South Florida CE Broker Provider #50-182.